49 results on '"Sattler, Martin"'
Search Results
2. Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors
3. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity
4. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
5. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
6. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
7. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy
8. Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis
9. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
10. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
11. The BCR/ABL Oncogene Alters the Chemotactic Response to Stromal-Derived Factor-1α
12. Hematopoietic Growth Factors Signal Through the Formation of Reactive Oxygen Species
13. The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis
14. The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment
15. Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens
16. Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells
17. Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells
18. The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma
19. Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128–350 Triggers MM Cell Death Via c- Jun Upregulation
20. Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.
21. BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production
22. Kinase Domain Mutations in JAK2V617F Confer Resistance to the Novel JAK2 Inhibitor Ruxolitinib
23. Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells
24. Mitochondrial Respiratory Chain Complex III Causes Genomic Instability In CML-CP.
25. The JAK2V617F Oncogene, Associated with Myeloproliferative Neoplasms, Requires Expression of Inducible Phosphofructokinase/Fructose Bisphosphatase 3 for Cell Growth and Increased Metabolic Activity
26. NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms.
27. Functional Oncogene Identification in Patient Leukemia Samples.
28. Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia
29. C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications
30. Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity
31. BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.
32. SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.
33. The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.
34. The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.
35. The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.
36. Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.
37. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
38. The Jak2V617F Oncogene Associated with Polycythemia Vera Regulates G1/S-Phase Transition.
39. Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.
40. Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.
41. How to interfere with FLT3
42. The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.
43. Pim Kinases Mediate Viability Signals Downstream of the Tyrosine Kinase Oncogenes BCR-ABL and FLT3-ITD.
44. Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.
45. Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).
46. 2-Methoxyestradiol alters cell motility, migration, and adhesion
47. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells
48. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Mycand Pimproto-oncogenes
49. Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128–350Triggers MM Cell Death Viac- Jun Upregulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.